Fundraising Fox
Opus Genetics
NASDAQ: IRDRaleigh, US · Founded 2021 · Delaware corporation · 46 employees on LinkedIn · 2 known investors
Find your way into Opus Genetics
Sign up to see every warm intro you have to Opus Genetics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Opus Genetics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Opus Genetics is a clinical-stage ophthalmic biopharmaceutical company developing therapies for inherited retinal diseases (IRDs) and other retinal and refractive disorders. It focuses on genetic medicine aimed at preserving and restoring vision for patients with rare eye conditions.
Founders & leadership
BH
Bernhard HoffmannExecutive
NJ
Nirav JhaveriChief Financial Officer2024–2025Nirav Jhaveri has spent over 25 years in capital markets and corporate finance roles at public and venture-backed biopharma companies, with experience in IPO preparation, fundraising, and business operations. He has held finance leadership positions guiding organizations through capital strategy and growth.
GM
George MagrathChief Executive OfficerGeorge Magrath is an ophthalmologist and CEO of Opus Genetics, a clinical-stage biopharmaceutical company developing gene therapies for inherited retinal diseases. He previously worked as an equity analyst covering biopharmaceutical companies, led drug development programs in respiratory, dermatology, and ophthalmology at Hovione, and served as CEO of Lexitas, where he oversaw organizational expansion and a strategic transaction.
BY
Ben YerxaPresidentHe brings over 30 years of experience in drug discovery, development, and commercialization across ophthalmology and rare disease, including leadership roles at Inspire Pharmaceuticals and as CEO of Foundation Fighting Blindness, and holds multiple issued US patents.
RG
Robert GagnonChief Financial Officer
JS
Joe SchachleChief Operating OfficerJoe Schachle is Chief Operating Officer at Opus Genetics, a clinical-stage biopharmaceutical company developing genetic therapies for inherited retinal diseases. He has held executive roles across large pharmaceutical and biotech firms, overseeing commercial, corporate, and operational functions including sales, marketing, finance, and strategic planning in ophthalmology and other therapeutic areas.
AJ
Ash JayagopalChief Scientific and Development OfficerAsh Jayagopal is Chief Scientific and Development Officer at Opus Genetics, a clinical-stage ophthalmic biopharmaceutical company focused on genetic medicine for inherited retinal diseases. He previously led ophthalmology R&D at Roche, where he contributed to the development of VABYSMO® and guided multiple gene therapies and large molecules through clinical development stages.
ST
Sally TuckerChief Medical OfficerSally Tucker holds a PhD in Ophthalmology and has led clinical trial operations and business development across pharmaceutical and medical device companies, including Top 30 pharma firms, with experience managing clinical research phases internationally and directing her own company.
ST
Sarah TullerChief Regulatory OfficerSarah Tuller is Chief Regulatory Officer at Opus Genetics, a clinical-stage ophthalmic biopharmaceutical company developing therapies for inherited retinal diseases. She has a legal and chemistry background with extensive regulatory affairs experience across biologics and drugs at both large and small companies, including managing regulatory teams and overseeing US and global marketing authorizations.
CE
Chris ErnstChief Technology OfficerChris Ernst is Chief Technology Officer at Opus Genetics, a clinical-stage ophthalmic biopharmaceutical company developing therapies for inherited retinal diseases. He brings expertise in quality assurance, regulatory affairs, and manufacturing oversight across biotechnology, CROs, and pharmaceutical companies, with specific experience in cell and gene therapy development and cGMP compliance.
AJ
Ashwath JayagopalChief Scientific and Development Officer
Investors · 2
Reported raises · per SEC filings
Form D private placements$60.9M disclosed across 4 rounds · 2020–2024
▶$25.8MraisedNov 2024 · 11 investors · BiotechnologyRule 506(b)
▶$25.8MraisedNov 2024 · 11 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Dr. Jean BennettDirector
- Dr. Benjamin YerxaDirector, Executive Officer
- Sean AinsworthDirector
- Bernhard HoffmannExecutive Officer
- Dr. Adrienne GravesDirector
- Richard RodgersDirector
- James ManusoDirector
- Nirav JhaveriExecutive Officer
- Ash JayagopalExecutive Officer
- Cam GallagherDirector
- Susan BentonDirector
- Amy RabournExecutive Officer
- Joseph SchachleExecutive Officer
- Dr. George MagrathDirector, Executive Officer
- Offering amount
- $25.8M
- Amount sold
- $25.8M
- First sale
- Oct 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$4.5MraisedJun 2023 · 5 investors · BiotechnologyRule 506(b)
▶$4.5MraisedJun 2023 · 5 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- JEAN BENNETTDirector
- RUSSELL KELLEYDirector
- BENJAMIN R. YERXAExecutive Officer, Director
- ADRIENNE GRAVESDirector
- Offering amount
- $20M
- Amount sold
- $4.5M
- First sale
- Jun 2023
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
▶$9.5MraisedAug 2021 · 5 investors · Other Health CareRule 506(b)
▶$9.5MraisedAug 2021 · 5 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- BENJAMIN R. YERXAExecutive Officer, Director
- JEAN BENNETTDirector
- RUSSELL KELLEYExecutive Officer, Director
- Offering amount
- $19M
- Amount sold
- $9.5M
- First sale
- Aug 2021
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
▶$21.1MraisedNov 2020 · 18 investors · BiotechnologyRule 506(b)
▶$21.1MraisedNov 2020 · 18 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- James S. ManusoDirector
- Mina SoochExecutive Officer, Director
- Alan R. MeyerDirector
- Sean AinsworthDirector
- Amy Zaremba RabournExecutive Officer
- Cam GallagherDirector
- Susan K. BentonDirector
- Richard J. RodgersDirector
- Bernhard HoffmannExecutive Officer
- Offering amount
- $21.1M
- Amount sold
- $21.1M
- Sales commissions
- $1.6M
- Placement agents
- Canaccord Genuity LLC, Cantor Fitzgerald & Co.
- First sale
- Nov 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Founder mafia
2 people who came through Opus Genetics went on to found or lead other companies.
Related companies · 3
NasdaqNasdaq operates a technology infrastructure platform for financial markets across three business segments: Capital Access Platforms (which includes listing services, indices, and analytics tools), Financial Technology (comprising compliance, regulatory, and capital markets software), and Market Services (equities and derivatives trading operations). The company serves financial institutions, listed companies, investment managers, and regulatory agencies globally.
OisOIS is a conference and community, active since 2009, focused on eye care and ophthalmology innovation, connecting startups, strategics, investors, and clinicians. It provides curated programming, networking, and access to new technologies in the ophthalmology industry.
Ocular TherapeutixOcular Therapeutix focuses on drug development and treatment for retinal diseases, with an emphasis on wet age-related macular degeneration and expanding into diabetic retinopathy conditions. The company aims to reduce therapeutic burden and improve patient outcomes in retinal care.
Companies working in the same space as Opus Genetics.
Frequently asked questions
- What does Opus Genetics do?
- Opus Genetics is a clinical-stage ophthalmic biopharmaceutical company developing therapies for inherited retinal diseases (IRDs) and other retinal and refractive disorders. It focuses on genetic medicine aimed at preserving and restoring vision for patients with rare eye conditions.
- Who are Opus Genetics's investors?
- Opus Genetics's investors include Michigan Capital Network, Oberland Capital.
- How much funding has Opus Genetics raised?
- Opus Genetics has disclosed $60.9M raised across 4 rounds.
- Where is Opus Genetics headquartered?
- Opus Genetics is headquartered in Raleigh, US.